Chlamydia pneumoniae and Mycoplasma pneumoniae

Francesco Blasi; P. Tarsia; S. Aliberti; R. Cosentini; L. Allegra

doi:10.1055/s-2005-925525

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2005; 26(6): 617-624
DOI: 10.1055/s-2005-925525

Chlamydia pneumoniae and Mycoplasma pneumoniae

Francesco Blasi¹ , P. Tarsia¹ , S. Aliberti¹ , R. Cosentini¹ , L. Allegra¹

¹Institute of Respiratory Diseases, University of Milan, IRCCS Fondazione Ospedale Maggiore Milano, Milan, Italy

Abstract

ABSTRACT

Mycoplasma. pneumoniae infection occurs worldwide and is the most common cause of community-acquired pneumonia (CAP) in 5- to 20-year-olds. The most reliable diagnostic test is the enzyme immunoassay, which allows immunoglobulin (Ig)G and IgM titration and presents 92% sensitivity and 95% specificity on paired samples. Potentially active drugs are tetracyclines, macrolides, ketolides, lincosamides, streptogamines, chloramphenicol, and fluoroquinolones. Chlamydia pneumoniae accounts for 6 to 20% of CAP cases, depending on several factors such as setting of the studied population, age group examined, and diagnostic methods used. The current gold standard for serological diagnosis of acute infection is microimmunofluorescence testing. Tetracyclines and erythromycin show good in vitro activity and so far have been the most commonly employed drugs in the treatment of C. pneumoniae infection. New macrolides, ketolides, and new fluoroquinolones are other potentially effective drugs.

KEYWORDS

Community-acquired pneumonia - atypical microorganisms - Mycoplasma pneumoniae - Chlamydia pneumoniae

Full Text

References

REFERENCES

1 Reimann H A. An acute infection of the respiratory tract with atypical pneumonia. JAMA. 1938; 111 2377-2384
2 Marrie T J, Peeling R W, Fine M J, Singer D E, Coley C M, Kapoor W N. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med. 1996; 101 509-515
3 Marston B J, Plouffe J F, File T M et al.. Incidence of community-acquired pneumonia requiring hospitalisation. Arch Intern Med. 1997; 157 1709-1718
4 Eaton M D, Meiklejohn G, van Herick W. Studies on the etiology of primary atypical pneumonia: a filtrable agent transmissible to cotton rats, hamster and chick embryos. J Exp Med. 1944; 79 649-668
5 Chanock R M, Dienes L, Eaton M D. Mycoplasma pneumoniae: proposed nomenclature for atypical pneumonia organism (Eaton agent). Science. 1963; 140 662
6 Chanock R M, Hayflick L, Barile M F. Growth on artificial medium of agent associated with atypical pneumonia and its identification as a PPLO. Proc Natl Acad Sci USA. 1962; 48 41-49
7 Couch R B. Mycoplasma pneumoniae (primary atypical pneumonia). In: Mandell GL, Douglas RG, Bennett JE Principles and Practice of Infectious Diseases. New York; John Wiley and Sons 1995: 1484
8 Foy H M, Kenny G E, Cooney M K, Allan I D. Long-term epidemiology of infections with Mycoplasma pneumoniae . J Infect Dis. 1979; 214 1666-1672
9 Foy H M, Kenny G E, McMahan R et al.. Mycoplasma pneumoniae pneumonia in an urban area. JAMA. 1970; 214 1666-1672
10 Murray H W, Masur H, Senterfit L B, Roberts R B. The protean manifestations of Mycoplasma pneumoniae infections in adults. Am J Med. 1975; 58 229-242
11 Levine D P, Lerner A M. The clinical spectrum of Mycoplasma pneumoniae infections. Med Clin North Am. 1978; 62 961-978
12 Rollins S, Colby T, Clayton F. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Arch Pathol Lab Med. 1986; 110 34-41
13 Marc E, Le Chaussain M, Moulin F et al.. Reduced lung diffusion capacity after Mycoplasma pneumoniae pneumonia. Pediatr Infect Dis J. 2000; 19 706-710
14 Tablan O C, Reyes M P. Chronic interstitial pulmonary fibrosis following Mycoplasma pneumoniae pneumonia. Am J Med. 1985; 79 268-270
15 Koletsky R J, Weinstein A J. Fulminant Mycoplasma pneumoniae infection: report of a fatal case and a review of the literature. Am Rev Respir Dis. 1980; 122 491-496
16 Halal F, Brochu P, Delage G. Severe disseminated lung disease and bronchiectasis probably due to Mycoplasma pneumoniae . Can Med Assoc J. 1977; 117 1055-1056
17 Rollins S, Colby T, Clayton F. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Arch Pathol Lab Med. 1986; 110 34-41
18 Grayston J T, Kuo C C, Campbell L A, Wang S P. Chlamydia pneumoniae sp. nov. for Chlamydia sp. strain TWAR. Int J Sys Bacteriol. 1989; 39 88-90
19 Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med. 1999; 106 385-390
20 Marrie T J, Peeling R W, Reid T, De Carolis E D. and the Canadian Community-Acquired Pneumonia Investigators . Chlamydia species as a cause of community-acquired pneumonia in Canada. Eur Respir J. 2003; 21 779-784
21 Grayston J T. Chlamydia pneumoniae strain TWAR. Chest. 1989; 95 664-669
22 Grayston J T, Campbell L A, Kuo C C et al.. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990; 161 618-625
23 Hirai Y, Shiode J, Masayoshi T, Kanemasa Y. Application of an indirect immunofluorescence test for the detection of Mycoplasma pneumoniae in respiratory exudates. J Clin Microbiol. 1991; 29 2007-2012
24 Kleemola M, Rati R, Karjalainen J et al.. Evaluation of an antigen-capture enzyme immunoassay for rapid diagnosis of Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis. 1993; 12 872-875
25 Madsen R D, Weiner L B, McMillan J A et al.. Direct detection of Mycoplasma pneumoniae antigen in clinical specimens by a monoclonal antibody immunoblot assay. Am J Clin Pathol. 1988; 89 95-99
26 Kleemola M, Jokinen C. Outbreak of Mycoplasma pneumoniae infection among hospital personnel studied by a nucleic acid hybridisation test. J Hosp Infect. 1992; 21 213-221
27 Kai M, Kamiya S, Yabe H et al.. Rapid detection of Mycoplasma pneumoniae in clinical samples by the polymerase chain reaction. J Med Microbiol. 1993; 38 166-170
28 Van Kuppelveld F J, Johansson K E, Galama J M et al.. 16S rRNA based polymerase chain reaction compared with culture and serological methods for diagnosis of Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis. 1994; 13 401-405
29 Smith T F. Mycoplasma pneumoniae infection: diagnosis based on immunofluorescence titre of IgG and IgM antibodies. Mayo Clin Proc. 1986; 61 830-831
30 Tompkins L S, Shachter J, Boman J et al.. Collaborative multidisciplinary workshop report: detection, culture, serology, and antimicrobial susceptibility testing of Chlamydia pneumoniae. . J Infect Dis. 2000; 181 S460-S461
31 Boman J, Söderberg S, Forsberg J et al.. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis. 1998; 178 274-277
32 Blasi F, Boman J, Esposito G et al.. Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. J Infect Dis. 1999; 180 2074-2076
33 Lucier T S, Heitzman K, Liu S K, Hu P C. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae . Antimicrob Agents Chemother. 1995; 39 2770-2773
34 Cooper M A, Baldwin D, Matthews R S, Andrews J M, Wise R. In vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics. J Antimicrob Chemother. 1991; 35 407-413
35 Hjelm E, Hulten K, Nystrom-Rosander C, Gustafsson I, Engstrand L, Cars O. Assay of antibiotic susceptibility of Chlamydia pneumoniae . Scand J Infect Dis. 1997; 104 (Suppl 104) 13-14
36 Hammerschlag M R, Qumei K K, Roblin P M. In vitro activities of azithromycin, clarithromycin, l-ofloxacin and other antibiotics against Chlamydia pneumoniae. . Antimicrob Agents Chemother. 1992; 36 1573-1574
37 Roblin P M, Montalban G, Hammerschlag M R. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother. 1994; 36 1573-1574
38 Roblin P M, Hammerschlag M R. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae . Antimicrob Agents Chemother. 1998; 42 1515-1516
39 Hammerschlag M R, Hyman C L, Roblin P M. In vitro activities of five quinolones against Chlamydia pneumoniae . Antimicrob Agents Chemother. 1992; 36 682-683
40 Roblin P M, Montalban G, Hammerschlag M R. In vitro activities of OPC-171 16, a new quinolone, ofloxacin and sparfloxacin against Chlamydia pneumoniae . Antimicrob Agents Chemother. 1994; 38 1402-1403
41 Kuo C-C, Grayston J T. In vitro drug susceptibility of Chlamydia SP. strain TWAR. Antimicrob Agents Chemother. 1988; 32 257-258
42 Mills G D, Oehley M R, Arrol B. Effectiveness of β-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ. 2005; 330 456
43 Kauppinen M T, Saikku P, Kujala P, Herva E, Syrjala H. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax. 1996; 51 185-189
44 Mandell L A, Marrie T J, Grossman R F, Chow A W, Hyland R H. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian community-acquired pneumonia working group. Clin Infect Dis. 2000; 31 383-421
45 Mandell L A, Bartlett J C, Dowell S F, File T M, Musher D M, Whitney C. Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults. Clin Infect Dis. 2003; 37 1405-1433
46 Principi N, Esposito S, Blasi F, Allegra L. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis. 2001; 32 1281-1289
47 Esposito S, Bosis S, Cavagna R et al.. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. Clin Infect Dis. 2002; 35 1345-1352
48 Blasi F. Atypical pathogens and respiratory tract infections. Eur Respir J. 2004; 24 171-181

Francesco BlasiM.D.

Institute of Respiratory Diseases, University of Milan, Pad. Sacco, IRCCS Fondazione Ospedale Maggiore di Milano, via F. Sforza 35, I-20122 Milan, Italy

Email: francesco.blasi@unimi.it